Maze Therapeutics (MAZE) Return on Capital Employed (2025 - 2026)
Maze Therapeutics (MAZE) posted Return on Capital Employed of 34.62% for Q1 2026, up 6.23% sequentially from 36.92% in Q4 2025, and down 5335.0% YoY from 0.66% in Q1 2025.
Maze Therapeutics (MAZE) Return on Capital Employed (2025 - 2026) Analysis & Trends
Maze Therapeutics has reported Return on Capital Employed for 2 years, with the latest figure at 34.62% in Q1 2026.
- Quarterly Return on Capital Employed fell 5335.0% year-over-year to 34.62% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 34.62% (down 5335.0% YoY) and the FY2025 annual result came in at 48.23%, changed N/A from the prior year.
- Return on Capital Employed rose to 34.62% in Q1 2026 per MAZE's latest filing, from 36.92% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 18.73% in Q1 2025 and troughed at 42.19% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Maze Therapeutics | 1.51 Bn | 1.51 Bn | - | -32.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -32.16% |
| Mar 31, 2026 | -34.62% |
| Dec 31, 2025 | -36.92% |
| Sep 30, 2025 | -39.50% |
| Jun 30, 2025 | -42.19% |
| Mar 31, 2025 | 18.73% |